A way out of the maze: Campylobacter jejuni gene polymorphisms define Guillain-Barré syndrome

Neurology

Volumn 65, Issue 9, 2005, Pages 1350-1351

  Wokke, John H J ^a   Van Den Berg, Leonard H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CROSS REACTING ANTIBODY; CYTOKINE; FC RECEPTOR; GANGLIOSIDE ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LIPOOLIGOSACCHARIDE; METHYLPREDNISOLONE;

ANTIBODY PRODUCING CELL; BACTERIAL INFECTION; CAMPYLOBACTER JEJUNI; CELL MEDIATED CYTOTOXICITY; CST II GENE; CYTOKINE PRODUCTION; DNA POLYMORPHISM; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; GENE; GUILLAIN BARRE SYNDROME; HUMAN; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; MOLECULAR MIMICRY; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHAGOCYTOSIS; PLASMAPHERESIS; PRIORITY JOURNAL; RISK FACTOR; SIALYLATION; T LYMPHOCYTE;

EID: 27644485872     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000185127.89668.7a     Document Type: Editorial

References (11)

1. Hadden RDM, Karch H, Hartung H-P, et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001;56:758-765.
2. Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995;333:1374-1379.
3. Van Sorge NM, Van der Pol, Jansen MD, et al. Severity of Guillain-Barré syndrome is associated with Fc gamma receptor space polymorphisms. J Neuroimmunol 2005;162:157-164.
4. Geleijns K, Laman JD, Van Rijs W, et al. Fas polymorphisms are associated with the presence of antiganglioside antibodies in Guillain-Barré syndrome. J Neurimmunol 2005;161:183-189.
5. Hughes RAC, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis 1997;176(suppl 2):S92-S98.
6. Ropper AH, Wijdicks EFM, Turk BT. Guillain-Barré syndrome. Philadelphia: FA Davis, 1991.
7. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;61:736-740.
8. Van Koningsveld R, Schmitz PIM, Van der Meché FGA, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004;363:192-196.
9. Koga M, Takahasi M, Masuda M, Hirata K, Yuki N. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome. Neurology 2005;65:1376-1381.
10. Koga M, Gilbert M, Li J, et al. Antecedent infections in Fisher syndrome. A common pathogenesis of molecular mimicry. Neurology 2005;64:1605-1611.
11. Gilbert M, Karwaski M-F, Bernatchez S, et al. The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni. J Biol Chem 2002;277:327-337.